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Abstract
Traumatic brain injury (TBI) is a major public health issue. The complexity of TBI has precluded the use of effective
therapies. Hyperbaric oxygen therapy (HBOT) has been shown to be neuroprotective in multiple neurological
disorders, but its efficacy in the management of TBI remains controversial. This review focuses on HBOT
applications within the context of experimental and clinical TBI. We also discuss its potential neuroprotective
mechanisms. Early or delayed multiple sessions of low atmospheric pressure HBOT can reduce intracranial pressure,
improve mortality, as well as promote neurobehavioral recovery. The complimentary, synergistic actions of HBOT
include improved tissue oxygenation and cellular metabolism, anti-apoptotic, and anti-inflammatory mechanisms.
Thus HBOT may serve as a promising neuroprotective strategy that when combined with other therapeutic targets
for TBI patients which could improve long-term outcomes.
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Introduction
Hyperbaric oxygen therapy (HBOT) is a treatment by
which 100% oxygen is administered to a patient at a
pressure greater than atmospheric pressure at sea level
(i.e. one atmosphere absolute, ATA) [1]. The increased
partial pressure of oxygen (pO2) within the blood and
subsequent improved mitochondrial metabolism/tissue
oxygenation constitutes the net effect of HBOT [2-6].
Given that the dissolved oxygen content in the plasma
increases linearly after hemoglobin is 100% saturated
[7,8], plasma bound oxygen can be used more readily
than that bound to hemoglobin which enables tissue
oxygen delivery even in the absence of red blood cells
[7,9].
Thus, HBOT induces a much larger oxygen-carrying
capacity in the blood that dramatically increases the
driving force of oxygen diffusion to tissues. Although
HBOT-induced cerebral vasoconstriction appears to be
undesirable within the context of ischemic conditions
[10,11] this may not be necessarily deleterious due to
increased oxygen availability to injured tissues. HBOT
may also counter vasodilation of the capillaries within
hypoxic tissues, thereby minimizing collection of extra-
vascular fluids (edema) which ultimately reduces brain
vasogenic edema and the ensuing decrease in intracra-
nial pressure (ICP) [5,12-14].
Emerging evidence has shown the neuroprotective
effects of HBOT in a range of multiple injuries and/or
disorders (Additional file 1, Table S1) [15]. The most
common clinical applications include decompression
sickness, carbon monoxide poisoning, minimization of
radiation therapy induced tissue damage and enhancing
skin grafts [1,16], which are all covered by insurance/
Medicare. There are numerous “unapproved” uses of
HBOT that focus on more complex neurological disor-
ders, including autism, multiple sclerosis and stroke,
which have shown promising results in experimental set-
tings, but clinical efficacy is still elusive. Recent efforts
have applied HBOT to traumatic brain injury [5,14,17].
While significant research on HBOT therapy has been
undertaken (> 10,000 citations on PubMed), very little
has been reported for HBOT within the setting of TBI
(< 30 citations). We now briefly review the experimental
and clinical HBO research relevant to TBI.
HBOT in animal models of TBI
Early experimental research focused on the effects of
HBO on brain edema, ICP and cerebral blood flow
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(CBF). Dunn and colleagues first demonstrated the neu-
roprotective effects of hyperoxia in a dog freeze-lesion
model of brain injury that simulated a brain contusion.
Hyperoxia significantly improved outcomes by reducing
mortality [18]. Reduced ICP (30% decrease) and CBF
(19%) were also reported in a dog model of brain injury
treated by HBOT (2 ATA for 4 hrs) [19]. The absence
of changes in cerebrospinal fluid (CSF) lactate, a marker
of brain injury, following HBOT further supported the
notion that HBO improved tissue oxygen delivery
despite the undesirable decrease in CBF subsequent to
vasoconstriction [10]. Expanding on the original model,
various methods (psyllium seed, extradural balloon)
were used to induce brain edema in dogs followed by
HBOT [20-23]. Using HBOT at 3 ATA for 45 min
[20,21] or at 2 ATA for 4 hrs [22] resulted in a signifi-
cant decrease (> 50%) in mortality relative to non-trea-
ted injured animals. They also reported significantly less
brain edema [20] and reduced cisternal CSF pressure
[21] in the HBOT groups. Sukoff and colleagues sug-
gested that the improvement seen in their model was
due to the effectiveness of HBOT against ischemia, sec-
ondary to the induced cerebral edema [21]. Hayakawa
et al, however, found that HBOT (3 ATA for 1 hr) did
not or barely changed CSF pressure and CBF in most
injured dogs [23].
In a rat model of moderate fluid percussion injury, the
neuroprotection afforded by HBOT translated into long
term cognitive improvements, characterized by a shorter
latency to find a hidden platform in Morris water maze
(MWM) performance [2]. Within brain tissues, HBOT
showed significant protection against hippocampal neuro-
nal loss compared to normobaric oxygen treatment [2].
Importantly, there was no increased free radial peroxide
and peroxynitrite production, suggesting the absence of
oxygen toxicity after HBOT [2]. Studies in a model of cer-
ebral ischemia concurred that HBOT did not exacerbate
lipid peroxidation [24].
The aforementioned neuroprotective efficacy of HBOT
was all achieved when intervention was administered dur-
ing the acute phase (within hours) of post-TBI. The pro-
longed therapeutic time window of HBOT was further
investigated in studies using a focal cortical weigh-drop
model of TBI [25-27]. Wang and colleagues have demon-
strated that multiple HBOT (3 ATA hourly for 3 or 5
days), delivered at latest 2 days post-injury resulted in sig-
nificantly reduced overall neurological deficit scores and
neuronal apoptosis within brain tissue. But the authors
also showed that twelve hours post-TBI is the latest effec-
tive window for neuroprotection when a single episode of
HBOT was delivered [27]. Moreover, Harch et al [25,26]
have tested the effects of low pressure HBOT (90 min
twice a day at 1.5 ATA) which started at 50 days after the
initial brain injury for a total duration of 40 days. At end
of the treatment (100 days post injury), MWM spatial
learning performance in the HBOT groups improved sig-
nificantly and was highly correlated with increased ipsilat-
eral hippocampal blood volume (cerebrovascular density)
measured by diaminobenzadine blood stain [25,26]. Given
the well-described presence of angiogenesis in HBOT in
other brain injury models [28,29], the authors suggested
that angiogenesis was the most likely explanation for the
HBOT-induced recovery of function. They claimed that
coupling of “blood flow and metabolism” and “metabolism
and function” were potential mechanisms, as both were
increased in animals receiving HBOT. This hypothesis is
consistent with the pattern of HBOT-induced increases in
blood flow seen on single photon emission computed
tomography brain imaging in patients with chronic TBI
[30,31]. A caveat is that HBOT failed to improve forelimb
placing function, likely due to the reported tissue loss
within the sensorimotor cortex following TBI [26].
We recently investigated both prophylactic (pre-treat-
ment) hyperbaric oxygen (HBO) strategy and HBOT (post-
treatment) for treatment of repetitive mild traumatic brain
injury (rmTBI) (personal communication: Drs. Lei Huang
and Andre Obenaus). Repetitive mTBI is an important
public health concern for sports athletes and active military
personnel as subsequent injuries are thought to exacerbate
existing neuropathology. Mild controlled cortical impact
(CCI) was used to model rmTBI in adult rats. In rmTBI
animals, a second mild CCI was delivered at the same loca-
tion at 3 or 7 days after the initial impact. HBO pre-treat-
ment or HBOT was given 1 hr daily at 2 ATA for 3
consecutive days either prior to or 24 hrs after the initial
TBI, respectively. T2 weighted imaging (T2WI) and sus-
ceptibility weighted imaging (SWI) were acquired non-
invasively from which lesion and hemorrhage volumes
were quantified. Our results clearly demonstrated that both
HBO pre-treatment and HBOT improved neuroimaging
outcomes following rmTBI, in contrast to those seen in tis-
sues without HBO intervention. There were significant
reductions in the T2WI-derived lesion and SWI-identified
hemorrhage volumes at 24 hrs after rmTBI (Figures 1, 2).
The most dramatic neuroprotective effects were observed
in animals receiving rmTBI 3 days apart where a 3-fold
reduction in hemorrhage volumes was observed compared
to Shams (Figure 2). Given that the pathophysiological pro-
cesses underlying rmTBI likely involves cellular metabolic
perturbations in the injured brain [32], a neuroprotective
approach, namely, HBO pre-treatment or HBOT favoring
cerebral aerobic metabolism could be beneficial. Similar
findings have been reported in HBOT for human severe
TBI [14].
Clinical HBOT for human TBI
A variety of human injuries and neurological diseases
have applied HBOT to improve outcomes. More overt
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neurological injuries, such as stroke or TBI have not been
aggressively pursued, partly due to apparent or perceived
contraindications. While a complete listing of the abso-
lute and relative contraindications for clinical applica-
tions are beyond the scope of this review, it should be
noted that certain drugs, fever and respiratory ailments
limit clinical application of HBOT. However, within the
realm of clinically applied HBOT for TBI very little
research has been conducted. Enthusiasm for HBOT for
brain injured patients was dampened by the findings of a
meta-analysis of TBI patients receiving HBOT [33]. Their
sobering conclusions were that the risk of death was
reduced but there was no apparent change in clinical out-
comes. However, as these authors acknowledged, var-
iance in treatment protocols and the limited number of
patients in the studies reviewed hampered their analysis.
Based on their findings they suggested that HBOT could
not be justified for TBI patients.
The poor clinical outcomes of earlier HBOT studies
combined with the relative success of normobaric oxygen
therapy (NBOT) in TBI have lead some to propose that
normobaric oxygen therapy should be used preferentially
in brain-injured patients. There are numerous studies
that demonstrate an enhanced clinical outcomes by treat-
ment with normobaric oxygen [34]. Much of the enthu-
siasm for use of NBOT is based on a prospective study of
severe TBI patients [4]. Narotam and colleagues [35]
evaluated brain tissue oxygen concentrations in patients
with severe TBI. Using Licox oxygen probes, 139 patients
were studied using a pO2 protocol that maintained brain
oxygen levels to > 20 mm Hg. They elegantly demon-
strated that normobaric oxygen therapy significantly
reduced mortality, but moreover, they showed improved
clinical outcomes at 6 mo post-severe TBI. A similar
study found that hyperoxia improved the cerebral meta-
bolic rate of oxygen in severe TBI patients using
Figure 1 HBO reduces rmTBI lesion volumes. Pre- and post-treatment with HBO reduces lesion volume identified from magnetic resonance
imaging (MRI, T2 weighted images). Repetitive mild traumatic brain injury (rmTBI) was induced 3 days apart and resulted in ipsilateral tissue
damage. On T2WI, hypointensities (white arrow) are consistent with bleeding while hyperintensities (black arrow) suggest edema formation. At
24 hrs after the rmTBI, HBO pre- or post-treatment significantly reduced the lesion size compared to untreated animals. The neuroprotective
effects persisted to 14 days after the initial mTBI.
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O15-postiron emission tomography, but they did not
compare to HBOT treated patients [36]. Thus, at a mini-
mum, NBOT could be beneficial for TBI patients.
The most extensive research into clinical application of
HBOT for TBI patients has been conducted by the Rock-
swolds [5,14,17,37]. Almost 30 years ago they undertook
one of the first clinical trials in evaluating the benefits of
HBOT for severe head injured patients [17]. In that early
study they demonstrated a 50% decrease in mortality but
found no changes in the clinical outcome status (i.e. good
recovery and moderate disability). As noted above, a meta-
analysis of several studies concluded the same findings;
reduced mortality but no change in clinical status [33].
While survival was increased, functional recovery was
not changed, leading to questions about the timing of the
HBOT. In addition, the mechanism(s) underlying HBOT
and its effects on cerebral metabolism had not been pre-
viously established in severely brain-injured patients. In
another prospective clinical trial, Rockswold et al [5],
reported increased cerebral metabolic rate of oxygen and
decreased lactate measured from cerebrospinal fluid after
HBOT (1.5 ATA 1 hr/day every 24 hrs with a maximum
of seven sessions). ICP was also reduced but a caveat was
noted that these changes did not last till the next session
[5]. It also serves to remind the reader that similar results
had also been previously reported in NBOT [36].
Based on evidence that NBOT of human TBI patients
appeared to have similar outcomes as patients who under-
went HBOT, a follow-up study was conducted to compare
these two groups after severe TBI to assess the efficacy of
therapy [14]. It is important to note, that the standard of
care is neither NBOT nor HBOT. Thus, their study design
included controls (standard of care), normobaric (3 hrs
100% O2) and HBOT (1.5 ATA for 60 min) that received
their initial treatment within 24 hrs of a severe TBI. Treat-
ments were then conducted daily for 3 consecutive days.
Figure 2 HBOT reduces extravascular blood after rmTBI. HBO pre- and post-treatment improved susceptibility weighted imaging (SWI)-
identified intracerebral hemorrhage following repetitive mild traumatic brain injury (rmTBI) 3 days apart. At 24 hrs after rmTBI, HBO pre- or post-
treatment significantly ameliorated the hemorrhage (hypointensity, asterisks) compared to untreated animals, which persisted to 14 days after
the initial mTBI.
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The pO2 levels within the brain were nearly 3 fold higher
in the HBOT compared to the NBOT groups and signifi-
cantly different from controls [14]. As previously reported,
they found increased cerebral metabolic rate of oxygen,
decreased lactate and decreased intracranial pressure.
They also reported that HBOT increased cerebral blood
flow. Perhaps the most important finding was that an indi-
cator of mitochondrial dysfunction, lactate/pyruvate ratios,
were significantly decreased only in the HBOT group.
They also demonstrated no adverse outcomes or harmful
effects in patients receiving HBOT [14]. Thus, HBOT for
severe TBI, appears to improve cellular survival which was
not observed in NBOT group.
Based on these limited studies, it is clear, that HBOT
could be an effective therapy for clinical severe TBI.
Compared to NBOT, HBOT assists in improving brain
“functions”, such as cerebral metabolism and blood flow.
However, additional studies are needed not only during
the acute phase of the injury, but also long-term studies
evaluating outcomes to determine if HBOT is beneficial
to TBI patients.
Putative mechanisms underlying the neuroprotection of
HBOT following TBI
Over the past several decades, the neuroprotective
mechanisms of HBOT have been investigated in a variety
of animal models of TBI. The initial work in dogs (see
above) have shown the HBOT was able to increase tissue
oxygen delivery [10] as well as to protect penumbra tissue
from secondary ischemia [21]. Based on the dog model, a
similar freeze-induced brain injury was conducted in rats
to evaluate local cerebral glucose utilization using the
autoradiographic 2-deoxyglucose technique. Compared to
animals that underwent NBOT, a four-day HBOT course
(2 ATA for 90 minutes daily) significantly reversed the
depressed glucose utilization within gray matter ipsilateral
to the lesion [38]. Interestingly, HBOT tended to decrease
glucose utilization in the sham-operated animals. How-
ever, it was still uncertain whether the favorable outcomes
were directly attributable to improved glucose metabolism
associated with HBOT. HBO-improvements in tissue oxy-
genation and mitochondrial metabolic function were
further investigated in a rat model of fluid percussion
injury (FPI) [3]. HBOT (1 hr 1.5 ATA with 3 hrs 100%
normobaric oxygen) treatments significantly improved, 1)
brain tissue pO2 (more than 6 fold) near the site of injury;
2) ex vivo brain tissue oxygen consumption (vO2, more
than 1 fold); and 3) recovery of synaptosomal mitochon-
drial metabolic activity [39,40].
Given that the prognosis of TBI clearly depends on the
processes of cell death and survival that occur within the
traumatized tissues, neuroprotective therapies need to
mitigate and improve survival and function within the
remaining viable perilesional brain tissue [41]. The
neuroprotective effects of HBOT against secondary brain
damage in the penumbra region have been extensively
investigated [6,41-43]. Using a model of dynamic cortical
deformation (DCD) to produce focal cerebral contusion in
rats, HBOT (2 sessions at 2.8 ATA for 45 min/each) were
administered at 3 hrs after TBI and compared to the
effects of NBOT. There were significantly smaller lesion
volumes and decreased numbers of terminal deoxynucleo-
tidyl transferase dUTP nick end labeling (TUNEL, a
biomarker for apoptosis) positive cells after HBOT.
Normobaric oxygen therapy (100%) also improved tissue
measures but not to the extent found after HBOT [43].
The anti-apoptotic modulator, B-cell lymphoma (Bcl-2),
was increased after HBOT and correlated to reduced tis-
sue apoptosis [41]. Similar changes were found for B-cell
lymphoma-extra large (Bcl-xl) expression, while the pro-
inflammatory protein, B-cell lymphoma-associated X pro-
tein (Bax), was observed primarily in astrocytes instead of
neurons. The ratio between pro-apoptotic Bax and anti-
apoptotic Bcl-2/Bcl-xl proteins has been shown to act as a
“rheostat” that sets the threshold [44] of susceptibility to
apoptosis by competitively modulating the opening of the
mitochondrial permeability transition pore (mPTP)
[45,46]. Enhanced Bcl-2 expression inhibits the mPTP that
subsequently preserves mitochondrial homeostasis and
therefore the integrity of the electron transport chain [6].
Palzur et al thus hypothesized that HBOT-induced
increases in Bcl-2 expression and the resultant increase in
intracellular oxygen bio-availability may contribute both to
preserve mitochondrial integrity and to reduce the activa-
tion of the mitochondrial mediated apoptotic pathway fol-
lowing TBI [6]. In the same animal model, HBOT (2.8
ATA for 45 min at 3 and 24 hrs post-injury) substantially
facilitated the recovery of mPTP expression. Subsequently,
TBI-induced injury to tissue morphology was reversed
with enhanced neuronal survival and preserved axonal
architecture within perislesional tissues [6]. Similar find-
ings of improved mitochondrial redox after HBOT in the
FPI model of TBI have also been reported [3]. The preser-
vation of mitochondrial integrity by HBOT hindered the
activation of mitochondria-associated apoptotic pathways
by significantly lowering caspase 3 and 9, but not caspase
8 expression (critical for non-mitochondrial apoptotic
pathway) in injured brain tissues [6]. These results under-
score the importance of HBOT-induced reductions in
delayed cell death within the tissue penumbra after TBI.
Such, mechanisms echo the neuroprotection of HBO seen
in brain ischemia and subarachnoid hemorrhage [47,48].
Acute inflammation also plays an important role in sec-
ondary brain damage after TBI. An influx of inflamma-
tory cells induced by TBI provides the primary source of
matrix metalloproteinases (MMPs) activity [49]. MMPs
in the injured brain further play a deleterious role and
promote cell death, including apoptosis [50]. The effects
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of HBOT on inflammatory infiltration and the expression
of (MMPs) have been explored in a rat model of DCD.
Both HBOT (2.8 ATA for 45 min at 3 hrs after injury
and twice a day thereafter for 3 consecutive days) and
NBOT significantly decreased myeloperoxidase-positive
neutrophils within the traumatic penumbra, but HBOT
had a more pronounced effect. HBOT also significantly
reduced the elevation of MMP-9 expression associated
with neutrophilic infiltration [42]. Thus, HBOT substan-
tially decreases the harmful effects of inflammation by
reducing MMP-9 over-expression that then results in a
reduction of delayed cell death in penumbral tissues
surrounding the site of injury. Interestingly, reduced
MMP-9 has also been proposed to be the underlying
mechanism associated with HBO pretreatment induced
neuroprotection against TBI at high altitude in a rat
model [51]. However, what is still unresolved is whether
the decreased numbers of apoptotic cells following
HBOT, is a direct anti-apoptotic effect or secondary con-
sequence due to HBOT anti-inflammatory effects.
Further studies are warranted to disclose the complex
mechanisms underlying the neuroprotective effects of
HBOT after TBI.
Conclusions
Translational research of HBOT in a variety of TBI models
has shown neuroprotective effects in the absence of
increased oxygen toxicity when administered at pressures
less than 3 ATA. Due to the heterogeneity of human TBI,
the efficacy of clinical HBOT and an optimal regimen for
HBOT remains elusive. However, all human studies have
involved severe TBI patients and it is likely that there may
be increased efficacy in mild or moderate TBI patients.
Recent clinical trials favor HBOT as promising safe thera-
peutic strategy for severe TBI patients. Although both
NBOT and 1.5 ATA HBOT can be neuroprotective,
HBOT exerts more robust and long-lasting effects in the
absence of pulmonary or cerebral oxygen toxicity. The
improved tissue oxygenation and cellular metabolism,
anti-apoptotic as well as anti-inflammatory effects may
constitute the multiple and complementary mechanisms
underlying HBOT-induced neuroprotection.
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